Potential benefits of rho-kinase inhibition in arterial hypertension
Related Experiment Video
Updated: May 9, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
1Department of Physiology, University of Greifswald, Greifswalder Str. 11c, 17495, Greifswald, Karlsburg, Germany, grisko@uni-greifswald.de.
Insights
New research explores Rho-kinases (ROCKs) as a target for hypertension treatment. ROCK inhibitors effectively lower blood pressure, offering potential for improved antihypertensive pharmacotherapy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Arterial hypertension is a leading global health issue, with many patients failing to achieve target blood pressure.
- Rho-kinases (ROCKs) play a role in hypertension development and progression.
Purpose of the Study:
- To evaluate the potential of pharmacological Rho-kinase (ROCK) inhibition as a novel antihypertensive therapy.
- To discuss the progress in understanding ROCK inhibitor mechanisms and developing selective agents.
Main Methods:
- Review of existing literature on ROCKs in hypertension.
- Analysis of studies on the blood pressure-lowering effects of ROCK inhibitors in preclinical and clinical settings.
Main Results:
- Pharmacological inhibition of ROCKs has demonstrated efficacy in reducing blood pressure in both experimental models and human patients.
- Non-selective ROCK inhibitors lower arterial pressure through various mechanisms.
Conclusions:
- ROCK inhibition represents a promising therapeutic strategy for managing arterial hypertension.
- Further research is needed to determine if ROCK inhibitors can significantly improve current antihypertensive pharmacotherapy options.
Abstract:
Arterial hypertension is a major health problem, accounting for 12 % of the global death rate. A large proportion of patients treated for high blood pressure do not reach target blood pressure values. The question arises if new antihypertensive drugs could improve present hypertension treatment. Rho-kinases (ROCKs) are ubiquitously expressed serine/threonine kinases and involved in a variety of cell functions. They contribute to the pathogenesis of human and experimental hypertension. Pharmacological ROCK inhibition has been shown to effectively lower blood pressure in patients and experimental animals. Progress has been made towards the understanding on how non-selective ROCK inhibitors lower arterial pressure and efforts are currently undertaken to develop ROCK inhibitors to improve their specificity and isoenzyme selectivity. If introduction of ROCK inhibitors for the treatment of high blood pressure can significantly advance currently available options of antihypertensive pharmacotherapy awaits further experimental and clinical research.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

